ALPS Key Statistics, Chart & Performance
The current stock price of ALPS is 0.9827 USD. In the past month the price decreased by -4.59%.
ALPS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About ALPS
Company Profile
Alps Group Inc is a MY-based company operating in Biotechnology industry. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2025-10-31. Alps Group Inc is the parent company of Alps Life Sciences Inc., an integrated biotechnology platform integrating research and development, medical services, and wellness solutions of advanced therapies under one unified ecosystem aimed at improving healthcare outcomes globally. The firm has cultivated a diverse pipeline covering various biotechnology research areas. This includes initiatives focused on MyImmune (NK cells), CAR-T cells, COVID-19 mRNA vaccine, diabetes therapeutics, and advancements in stem cell technologies such as induced Pluripotent Stem Cells (iPSCs) and messenger ribonucleic acid (mRNA) platform technology. The firm provides aesthetic treatments, cosmetic procedures, general healthcare and wellness services. The Company’s aesthetic services and cosmetic surgery services include non-surgical aesthetic services and surgical aesthetic services. The company operates a molecular laboratory and a cGMP cell and gene therapy research and cultivation laboratory.
Company Info
ALPS GROUP INC
Unit E-18-01 & E-18-02, Level 18,, Icon Tower (East), No.1,Jalan 1/68F,
KUALA LUMPUR WILAYAH PERSEKUTUAN MY
Employees: 0
Phone: 60321631113
ALPS GROUP INC / ALPS FAQ
What does ALPS do?
Alps Group Inc is a MY-based company operating in Biotechnology industry. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2025-10-31. Alps Group Inc is the parent company of Alps Life Sciences Inc., an integrated biotechnology platform integrating research and development, medical services, and wellness solutions of advanced therapies under one unified ecosystem aimed at improving healthcare outcomes globally. The firm has cultivated a diverse pipeline covering various biotechnology research areas. This includes initiatives focused on MyImmune (NK cells), CAR-T cells, COVID-19 mRNA vaccine, diabetes therapeutics, and advancements in stem cell technologies such as induced Pluripotent Stem Cells (iPSCs) and messenger ribonucleic acid (mRNA) platform technology. The firm provides aesthetic treatments, cosmetic procedures, general healthcare and wellness services. The Company’s aesthetic services and cosmetic surgery services include non-surgical aesthetic services and surgical aesthetic services. The company operates a molecular laboratory and a cGMP cell and gene therapy research and cultivation laboratory.
What is the stock price of ALPS GROUP INC today?
The current stock price of ALPS is 0.9827 USD. The price increased by 0.79% in the last trading session.
Does ALPS GROUP INC pay dividends?
ALPS does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALPS stock?
ALPS has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for ALPS stock?
ALPS GROUP INC (ALPS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.17).
What is ALPS GROUP INC worth?
ALPS GROUP INC (ALPS) has a market capitalization of 163.52M USD. This makes ALPS a Micro Cap stock.
ALPS Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ALPS.
ALPS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALPS. ALPS may be in some trouble as it scores bad on both profitability and health.
ALPS Financial Highlights
Over the last trailing twelve months ALPS reported a non-GAAP Earnings per Share(EPS) of -0.17. The EPS decreased by -216.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.77% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |